Filing Details
- Accession Number:
- 0001209191-21-009921
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-11 20:02:16
- Reporting Period:
- 2021-02-09
- Accepted Time:
- 2021-02-11 20:02:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1340652 | Chemocentryx Inc. | CCXI | Pharmaceutical Preparations (2834) | 943254365 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1422995 | J. Markus Cappel | C/O Chemocentryx, Inc. 850 Maude Avenue Mountain View CA 94043 | Chief Bus. Officer & Treasurer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-02-09 | 700 | $11.02 | 86,526 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-02-09 | 700 | $69.66 | 85,826 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2021-02-09 | 700 | $0.00 | 700 | $11.02 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
58,300 | 2029-03-04 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $69.50 to $70.07 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- As of February 9, 2021, and prior to this transaction, the exercised options were fully vested.
- Not applicable.